KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Accumulated Depreciation (2016 - 2018)

Arbutus Biopharma (ABUS) has disclosed Accumulated Depreciation for 9 consecutive years, with $6.9 million as the latest value for Q4 2018.

  • Quarterly Accumulated Depreciation fell 45.58% to $6.9 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2018, down 45.58% year-over-year, with the annual reading at $6.9 million for FY2018, 45.58% down from the prior year.
  • Accumulated Depreciation hit $6.9 million in Q4 2018 for Arbutus Biopharma, up from $6.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $13.3 million in Q1 2018 to a low of $5.9 million in Q2 2018.
  • Historically, Accumulated Depreciation has averaged $10.4 million across 5 years, with a median of $10.6 million in 2016.
  • Biggest YoY gain for Accumulated Depreciation was 19.8% in 2018; the steepest drop was 48.92% in 2018.
  • Year by year, Accumulated Depreciation stood at $11.2 million in 2014, then decreased by 13.13% to $9.7 million in 2015, then increased by 10.37% to $10.7 million in 2016, then grew by 18.0% to $12.7 million in 2017, then crashed by 45.58% to $6.9 million in 2018.
  • Business Quant data shows Accumulated Depreciation for ABUS at $6.9 million in Q4 2018, $6.4 million in Q3 2018, and $5.9 million in Q2 2018.